Newswise — BOSTON – (February 3, 2015) – Joslin Diabetes Center announced today that Insulet Corporation (NASDAQ: PODD), has joined the Joslin Institute for Technology Translation (JITT) as a Founding Member.
JITT, an innovation group at Joslin, is focused on leveraging the potential of technology with the introduction of clinical solutions, decision support tools and the advancement of digital health to improve the lives of people with diabetes.
Insulet Corporation is a medical device company based in Billerica, Massachusetts. It was founded in 2000 with the mission of making the lives of people with diabetes easier, specifically through its revolutionary tubeless OmniPod Insulin Management System.
“Our patients are always interested in new innovative solutions and the OmniPod System is an example of that,” said Howard Wolpert, M.D., Director of the Insulin Pump and Continuous Glucose Monitoring Programs at Joslin and Associate Professor of Medicine at Harvard Medical School. “We are excited to have Insulet as a Founding Member and look forward to collaborating with them around improving care for people with diabetes.”
“We are very pleased to welcome Insulet to the Joslin Institute for Technology Translation (JITT),” said Harry Mitchell, Executive Director of JITT. “We are eager to work with the Insulet Team in furthering our joint goal of advancing diabetes care.”
“Insulet is pleased to partner with the JITT to further our shared mission of improving the lives of people living with diabetes,” said Patrick Sullivan, President and Chief Executive Officer of Insulet. “We are committed to making diabetes a smaller part of life for all people affected and our collaboration with the esteemed Joslin Diabetes Center will certainly benefit this concentrated effort.”
About Joslin Institute for Technology Translation (JITT)
Joslin Institute for Technology Translation is focused on leveraging the potential of technology with the introduction of clinical solutions and digital health to improve the lives of people with diabetes. JITT pairs Joslin Diabetes Center’s clinical expertise with industry to enhance the development of new and clinically effective technologies and digital health tools; it is uniquely positioned to provide clinical insight for medical devices, technologies and strategies for cost-efficient solutions that improve diabetes care and outcomes.
About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care. Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit www.joslin.org.
About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor of diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit the customer blog, Suite D: http://suited.myomnipod.com/. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com/.
Joslin Diabetes Center and the Joslin Institute for Technology Translation do not promote or endorse any product. Revenue and fees received by JITT will be invested in digital health to improve patient care.
###
RSS